A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples